Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms

被引:423
作者
Jackson, Shaun P. [1 ,2 ,3 ]
Darbousset, Roxane [1 ,2 ]
Schoenwaelder, Simone M. [1 ,2 ]
机构
[1] Heart Res Inst, Newtown, NSW, Australia
[2] Univ Sydney, Charles Perkins Ctr, Level 3,D17,Orphan Sch Creek Rd, Camperdown, NSW 2006, Australia
[3] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA
基金
英国医学研究理事会;
关键词
FACTOR PATHWAY INHIBITOR; ACTIVATED PROTEIN-C; HUMAN SOLUBLE THROMBOMODULIN; PLATELET GPIIB/IIIA RECEPTOR; ISCHEMIA-REPERFUSION INJURY; TISSUE FACTOR; FACTOR-XI; SEVERE SEPSIS; MICROCIRCULATORY ALTERATIONS; PROCOAGULANT PLATELETS;
D O I
10.1182/blood-2018-11-882993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombosis with associated inflammation (thromboinflammation) occurs commonly in a broad range of human disorders. It is well recognized clinically in the context of superficial thrombophlebitis (thrombosis and inflammation of superficial veins); however, it is more dangerous when it develops in the microvasculature of injured tissues and organs. Microvascular thrombosis with associated inflammation is well recognized in the context of sepsis and ischemia-reperfusion injury; however, it also occurs in organ transplant rejection, major trauma, severe burns, the antiphospholipid syndrome, preeclampsia, sickle cell disease, and biomaterial-induced thromboinflammation. Central to thromboinflammation is the loss of the normal antithrombotic and anti-inflammatory functions of endothelial cells, leading to dysregulation of coagulation, complement, platelet activation, and leukocyte recruitment in the microvasculature. alpha-Thrombin plays a critical role in coordinating thrombotic and inflammatory responses and has long been considered an attractive therapeutic target to reduce thromboinflammatory complications. This review focuses on the role of basic aspects of coagulation and alpha-thrombin in promoting thromboinflammatory responses and discusses insights gained from clinical trials on the effects of various inhibitors of coagulation on thromboinflammatory disorders. Studies in sepsis patients have been particularly informative because, despite using anticoagulant approaches with different pharmacological profiles, which act at distinct points in the coagulation cascade, bleeding complications continue to undermine clinical benefit. Future advances may require the development of therapeutics with primary antiinflammatory and cytoprotective properties, which have less impact on hemostasis. This may be possible with the growing recognition that components of blood coagulation and platelets have prothrombotic and proinflammatory functions independent of their hemostatic effects.
引用
收藏
页码:906 / 918
页数:13
相关论文
共 135 条
  • [1] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
    Abraham, E
    Reinhart, K
    Svoboda, P
    Seibert, A
    Olthoff, D
    Dal Nogare, A
    Postier, R
    Hempelmann, G
    Butler, T
    Martin, E
    Zwingelstein, C
    Percell, S
    Shu, V
    Leighton, A
    Creasey, AA
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (11) : 2081 - 2089
  • [2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
    Abraham, E
    Reinhart, K
    Opal, S
    Demeyer, I
    Doig, C
    Rodriguez, AL
    Beale, R
    Svoboda, P
    Laterre, PF
    Simon, S
    Light, B
    Spapen, H
    Stone, J
    Seibert, A
    Peckelsen, C
    De Deyne, C
    Postier, R
    Pettilä, V
    Sprung, CL
    Artigas, A
    Percell, SR
    Shu, V
    Zwingelstein, C
    Tobias, J
    Poole, L
    Stolzenbach, JC
    Creasey, AA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02): : 238 - 247
  • [3] Structure, function and pathophysiology of protease activated receptors
    Adams, Mark N.
    Ramachandran, Rithwik
    Yau, Mei-Kwan
    Suen, Jacky Y.
    Fairlie, David P.
    Hollenberg, Morley D.
    Hooper, John D.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2011, 130 (03) : 248 - 282
  • [4] The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
    Aird, WC
    [J]. BLOOD, 2003, 101 (10) : 3765 - 3777
  • [5] Spatial and temporal dynamics of the endothelium
    Aird, WC
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (07) : 1392 - 1406
  • [6] Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar
    Aisiku, Omozuanvbo
    Peters, Christian G.
    De Ceunynck, Karen
    Ghosh, Chandra C.
    Dilks, James R.
    Fustolo-Gunnink, Susanna F.
    Huang, Mingdong
    Dockendorff, Chris
    Parikh, Samir M.
    Flaumenhaft, Robert
    [J]. BLOOD, 2015, 125 (12) : 1976 - 1985
  • [7] Use of antiplatelet agents in sepsis: A glimpse into the future
    Akinosoglou, Karolina
    Alexopoulos, Dimitrios
    [J]. THROMBOSIS RESEARCH, 2014, 133 (02) : 131 - 138
  • [8] Allen Karen S, 2015, World J Crit Care Med, V4, P105, DOI 10.5492/wjccm.v4.i2.105
  • [9] Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis
    Allingstrup, Mikkel
    Wetterslev, Jorn
    Ravn, Frederikke B.
    Moller, Ann Merete
    Afshari, Arash
    [J]. INTENSIVE CARE MEDICINE, 2016, 42 (04) : 505 - 520
  • [10] Alvarez P, 2015, Open Respir Med J, V9, P92, DOI 10.2174/1874306401509010092